Rational Modification of a Candidate Cancer Drug for Use Against Chagas Disease
Citations Over TimeTop 10% of 2009 papers
Abstract
Chagas disease is one of the major neglected diseases of the world. Existing drug therapies are limited, ineffective, and highly toxic. We describe a novel strategy of drug discovery of adapting an existing clinical compound with excellent pharmaceutical properties to target a pathogenic organism. The protein farnesyltransferase (PFT) inhibitor tipifarnib, now in phase III anticancer clinical trials, was previously found to kill Trypanosoma cruzi by blocking sterol 14 alpha-demethylase (14DM). We rationally developed tipifarnib analogues that display reduced affinity for human PFT to reduce toxicity while increasing affinity for parasite 14DM. The lead compound has picomolar activity against cultured T. cruzi and is efficacious in a mouse model of acute Chagas disease.
Related Papers
- → Evidence of Trypanosoma cruzi II infection in Colombian chagasic patients(2008)58 cited
- → Discovery and Optimization of a Compound Series Active against Trypanosoma cruzi, the Causative Agent of Chagas Disease(2020)12 cited
- → N4-substituted N1-(3-Dimethylaminopropyl)-piperazines : a New Series of Compounds active against Trypanosoma cruzi Infections in Mice(1965)7 cited
- → The reception by French physicians of Chagas' discovery of Trypanosoma cruzi and American trypanosomiasis (1909-1925)(2009)3 cited
- → Discovery and Optimization\nof a Compound Series Active\nagainst <i>Trypanosoma cruzi</i>, the Causative Agent of\nChagas Disease(2020)